Francis Medical's Vanquish wields water vapor to overcome some of the limitations of traditional thermal ablation by applying high pressure in 10-second bursts through a catheter. (Francis Medical) ...

Francis’ ongoing VAPOR 2 single-arm study aims to support a 510(k) application for Vanquish at the FDA this July, with one-year data from 235 patients diagnosed with localized, intermediate-risk ...

Francis Medical’s Vanquish device for treating intermediate-risk prostate cancer has been cleared by the US Food and Drug Administration (FDA). Vanquish is a transurethral, ultrasound and ...

MINNEAPOLIS, Dec. 2, 2025 /PRNewswire/ -- Francis Medical, Inc., a privately-held medical device company developing the breakthrough Vanquish® Water Vapor Ablation System for the management of ...

Agreement provides Profound with increased access to urologists via a strong strategic partner and creates a framework to further advance clinical evidence-based patient selection and optimization of ...

Francis Medical – a privately-held medical device company developing an innovative and proprietary water vapor ablation therapy for the treatment of prostate, kidney, and bladder cancer- announced the ...

TORONTO, April 01, 2026 (GLOBE NEWSWIRE)-- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, ...

LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, and HALO ...

91% of men with a single GG2 prostate tumor treated with water therapy partial gland ablation showed GG1 or benign tissue in their 6-month MRI-targeted biopsy samples. In men with favorable ...

Profound Medical (NASDAQ:PROF) and Telix Pharmaceuticals (NASDAQ:TLX) have signed a co-education agreement aimed at increasing physician awareness of how advanced diagnostic imaging can support ...